BioMaxima S.A. (WSE:BMX)
Poland
· Delayed Price · Currency is PLN 11.75
+0.10 (0.86%)
At close: Dec 5, 2025
BioMaxima Revenue
BioMaxima had revenue of 15.91M PLN in the quarter ending September 30, 2025, with 10.23% growth. This brings the company's revenue in the last twelve months to 59.68M, up 15.27% year-over-year. In the year 2024, BioMaxima had annual revenue of 52.85M with 12.96% growth.
Revenue (ttm)
59.68M
Revenue Growth
+15.27%
P/S Ratio
0.83
Revenue / Employee
469.14K
Employees
126
Market Cap
49.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52.85M | 6.07M | 12.96% |
| Dec 31, 2023 | 46.79M | -97.08M | -67.48% |
| Dec 31, 2022 | 143.87M | 64.78M | 81.91% |
| Dec 31, 2021 | 79.09M | 17.81M | 29.06% |
| Dec 31, 2020 | 61.28M | 30.67M | 100.19% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Diagnostyka | 2.30B |
| NEUCA | 13.34B |
| Synektik Spólka Akcyjna | 623.20M |
| Voxel | 568.83M |
| Celon Pharma | 225.60M |
| Selvita | 373.90M |
| Ryvu Therapeutics | 90.41M |
| Centrum Medyczne ENEL-MED | 820.59M |